A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Mental Health Issue
Interventions
DRUG

Colistimethate sodium for injection

Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.

DRUG

Meropenem for Injection

Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.

DRUG

Coly Mycin M Injectable Product

Coly Mycin M is the originally marketed colistimethate sodium for injection.

Trial Locations (32)

100069

RECRUITING

Beijing You'an Hospital, Capital Medical University, Beijing

110002

RECRUITING

The First Hospital of China Medical University, Shenyang

110031

RECRUITING

General Hospital of Northern Theater Command, Shenyang

130041

RECRUITING

The Second Norman Bethune Hospital of Jilin University, Changchun

130061

RECRUITING

The first hospital of Jilin University, Changchun

200000

RECRUITING

Huashan Hospital Affiliated to Fudan University, Shanghai

200040

RECRUITING

Huadong Hospital affiliated to Fudan University, Shanghai

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

201899

RECRUITING

Shanghai Jiading District Central Hospital, Shanghai

210002

RECRUITING

General Hospital of the Eastern Theater Command, Nanjing

223022

RECRUITING

Huai'an Second People's Hospital, Huaian

225003

RECRUITING

Jiangsu Subei People's Hospital, Yangzhou

225399

RECRUITING

Taizhou Hospital of TCM, Taizhou

233099

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

247099

RECRUITING

The People's Hospital of Chizhou, Chizhou

300222

ACTIVE_NOT_RECRUITING

Tianjin Chest Hospital, Tianjin

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

361004

RECRUITING

Zhongshan Hospital Xiamen University, Xiamen

401320

RECRUITING

People's Hospital of Chongqing Banan District, Chongqing

402260

RECRUITING

Chongqing University Jiangjin Hospital, Chongqing

410002

RECRUITING

Hunan Provincial People's Hospital, Changsha

410008

RECRUITING

Xiangya Hospital Central South University, Changsha

410028

RECRUITING

Changsha Central Hospital, Changsha

441021

RECRUITING

Xiangyang Central Hospital, Xiangyang

471099

RECRUITING

Luoyang Central Hospital, Luoyang

472099

RECRUITING

Sanmenxia Central Hospital, Sanmenxia

510260

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

515041

RECRUITING

The First Affiliated Hospital of Shantou University School of Medicine, Shantou

610044

RECRUITING

West China Hospital, Sichuan University, Chengdu

830054

RECRUITING

The First Hospital of Xinjiang Medical University, Ürümqi

046099

RECRUITING

Changzhi People's Hospital, Changzhi

030001

RECRUITING

The First Hospital of Shanxi Medical University, Taiyuan

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06198764 - A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection | Biotech Hunter | Biotech Hunter